Evidence map›Paper›PMID 17570320›Full record

Trial reportInternational immunopharmacology2007

Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Rakesh K Singh, Michelle L Varney, Cheryl Leutzinger, Julie M Vose, Philip J Bierman, Suleyman Buyukberber, Kazuhiko Ino, Kevin Loh, Craig Nichols, David Inwards and 2 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in International immunopharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Rakesh K SinghDepartment of Pathology and Microbiology, University of Nebraska Medical Center 987660, Omaha, NE 68198-7660, USA. rsingh@unmc.edu
Michelle L Varney
Cheryl Leutzinger
Julie M Vose
Philip J Bierman
Suleyman Buyukberber
Kazuhiko Ino
Kevin Loh
Craig Nichols
David Inwards
Robert Rifkin
James E Talmadge
University of Nebraska Medical Center · USGaziantep University · TRMayo Clinic · USNagoya University · JPOregon Health & Science University · USRocky Mountain Cancer Centers · US

Funding

Molecular Regulation of Human Melanoma MetastasisR01CA072781 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SINGH, RAKESH K · 2005 to 2007
$580k
MOLECULAR REGULATION OF HUMAN MELANOMA METASTASISR29CA072781 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SINGH, RAKESH K · 1998 to 2002
$308k
T-CELLS AND TRANSPLANTATION THERAPIESR01CA061593 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI TALMADGE, JAMES E · 1993 to 1996
–
NCI NIH HHS CA72781NCI NIH HHS R01 CA061593NCI NIH HHS R01 CA072781NCI NIH HHS R29 CA072781
6 · The paper itself

Abstract

In sequential studies, we compared immune reconstitution following high-dose chemotherapy (HDT) and stem cell transplantation (SCT) using intact mobilized peripheral blood stem cell (PSC) in intermediate grade non-Hodgkin's lymphoma (NHL) patients and CD34(+), lineage-negative (Lin(-)), Thy-1(lo) (CD34(+)Lin(-)Thy-1(lo)) stem cells in low-grade NHL patients. Cytokine expression and cellular phenotype and function were used as the basis of comparison. Despite differences in cellular composition of the stem cell grafts, immune reconstitution in both groups was similar. Significantly higher levels of type 1- and 2-associated cytokine messenger ribonucleic acid (mRNA) were observed both prior to and following transplant in the peripheral blood (PB) of both cohorts as compared to normal individuals. Similar levels of interleukin (IL)-4, IL-10, interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha) messenger ribonucleic acid (mRNA) were seen in PB mononuclear cells following transplant with either product. In contrast, patients receiving isolated CD34(+)Lin(-)Thy-1(lo) cells expressed significantly higher IL-2 levels at all times examined post-transplant. Despite the high levels of cytokine gene expression and rapid restoration to pretransplant levels of CD3 cell number by day 30, T cell function and CD4:CD8 and CD4(+)CD45RA:CD4(+)CD45RO(+) ratios were significantly depressed in both cohorts compared to normal donors, and significantly lower in patients transplanted with CD34(+)Lin(-)Thy-1(lo) compared to patients receiving an intact PSC product. These data suggest that the peripheral tolerance in patients receiving HDT and an autologous SCT occurs independent of graft composition, although immune function and CD4 recovery are better facilitated by transplantation of an intact product.

Indexed as

AdultAntigens, CD34Combined Modality TherapyFemaleGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell TransplantationHumansInjections, SubcutaneousInterferon-alphaInterferon-gammaInterleukinsLymphoma, Non-HodgkinMaleMiddle AgedRecovery of FunctionRNA, MessengerAntigens, CD34Granulocyte Colony-Stimulating FactorInterferon-alphaInterferon-gammaInterleukinsRNA, MessengerThy-1 Antigens

Identifiers

PMID17570320
PMCPMC2034447
OpenAlexW2090976273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.